Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:INM NASDAQ:NCEL NASDAQ:SNSE NASDAQ:TVRD On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeINMInMed Pharmaceuticals$1.59+2.6%$1.26$0.58▼$3.28$5.14M0.9554,301 shs57,764 shsNCELNLS Pharmaceutics$3.85+5.2%$3.43$1.83▼$28.03$19.56M0.9314,091 shs181,538 shsSNSESensei Biotherapeutics$14.15+2.1%$19.01$5.86▼$36.76$18.98M-0.2553,599 shs219,729 shsTVRDTvardi Therapeutics$1.95+2.6%$3.11$1.50▼$43.65$17.83M0.4385,365 shs167,959 shs(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceINMInMed Pharmaceuticals+2.58%+2.58%+1.92%+134.51%-48.54%NCELNLS Pharmaceutics+5.19%+7.24%+10.63%+70.35%-86.54%SNSESensei Biotherapeutics0.00%0.00%-28.52%-54.40%+59.83%TVRDTvardi Therapeutics+2.63%-17.02%-39.44%-35.43%-91.20%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeINMInMed Pharmaceuticals$1.59+2.6%$1.26$0.58▼$3.28$5.14M0.9554,301 shs57,764 shsNCELNLS Pharmaceutics$3.85+5.2%$3.43$1.83▼$28.03$19.56M0.9314,091 shs181,538 shsSNSESensei Biotherapeutics$14.15+2.1%$19.01$5.86▼$36.76$18.98M-0.2553,599 shs219,729 shsTVRDTvardi Therapeutics$1.95+2.6%$3.11$1.50▼$43.65$17.83M0.4385,365 shs167,959 shs(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceINMInMed Pharmaceuticals+2.58%+2.58%+1.92%+134.51%-48.54%NCELNLS Pharmaceutics+5.19%+7.24%+10.63%+70.35%-86.54%SNSESensei Biotherapeutics0.00%0.00%-28.52%-54.40%+59.83%TVRDTvardi Therapeutics+2.63%-17.02%-39.44%-35.43%-91.20%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceINMInMed Pharmaceuticals 1.00SellN/AN/ANCELNLS Pharmaceutics 1.00SellN/AN/ASNSESensei Biotherapeutics 2.43Hold$48.00239.34% UpsideTVRDTvardi Therapeutics 2.50Moderate Buy$39.801,941.03% UpsideCurrent Analyst Ratings BreakdownLatest INM, NCEL, SNSE, and TVRD Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/29/2026NCELNLS Pharmaceutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E)6/24/2026INMInMed Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)6/11/2026SNSESensei Biotherapeutics BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$55.006/8/2026TVRDTvardi Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$9.006/4/2026SNSESensei Biotherapeutics Cantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight5/29/2026SNSESensei Biotherapeutics Cantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOverweight5/28/2026SNSESensei Biotherapeutics Loop CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$50.005/22/2026SNSESensei Biotherapeutics CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$55.004/24/2026SNSESensei Biotherapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/21/2026INMInMed Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)4/21/2026SNSESensei Biotherapeutics Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold(Data available from 7/2/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookINMInMed Pharmaceuticals$4.94M1.07N/AN/A$6.71 per share0.24NCELNLS PharmaceuticsN/AN/AN/AN/A$1.59 per shareN/ASNSESensei BiotherapeuticsN/AN/AN/AN/A$14.74 per shareN/ATVRDTvardi Therapeutics$7.14M2.56N/AN/A$2.23 per share0.87Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateINMInMed Pharmaceuticals-$8.16M-$2.89N/AN/AN/A-132.87%-80.85%-68.11%9/18/2026 (Estimated)NCELNLS Pharmaceutics-$8.30MN/AN/AN/AN/AN/AN/AN/AN/ASNSESensei Biotherapeutics-$21.08M-$142.72N/AN/AN/AN/A-83.59%-256.50%8/4/2026 (Estimated)TVRDTvardi Therapeutics-$18.21M-$3.10N/AN/AN/AN/A-64.17%-43.90%N/ALatest INM, NCEL, SNSE, and TVRD EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2026Q4 2025SNSESensei Biotherapeutics-$0.62-$131.45-$130.83-$131.45N/AN/A5/8/2026Q1 2026TVRDTvardi Therapeutics-$0.65-$0.73-$0.08-$0.73N/AN/A5/6/2026Q3 2026INMInMed Pharmaceuticals-$94.4436-$0.69+$93.7536-$0.73$1.20 millionN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthINMInMed PharmaceuticalsN/AN/AN/AN/AN/ANCELNLS PharmaceuticsN/AN/AN/AN/AN/ASNSESensei BiotherapeuticsN/AN/AN/AN/AN/ATVRDTvardi TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioINMInMed PharmaceuticalsN/A3.123.12NCELNLS PharmaceuticsN/A0.760.76SNSESensei BiotherapeuticsN/A14.3914.39TVRDTvardi TherapeuticsN/A2.252.25Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipINMInMed Pharmaceuticals20.12%NCELNLS PharmaceuticsN/ASNSESensei Biotherapeutics10.50%TVRDTvardi Therapeutics44.66%Insider OwnershipCompanyInsider OwnershipINMInMed Pharmaceuticals0.85%NCELNLS Pharmaceutics16.40%SNSESensei Biotherapeutics7.00%TVRDTvardi Therapeutics7.40%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableINMInMed Pharmaceuticals103.31 million3.29 millionNot OptionableNCELNLS Pharmaceutics65.35 million4.47 millionNot OptionableSNSESensei Biotherapeutics401.34 million1.25 millionNot OptionableTVRDTvardi Therapeutics809.38 million8.69 millionN/AINM, NCEL, SNSE, and TVRD HeadlinesRecent News About These CompaniesTvardi Therapeutics (NASDAQ:TVRD) Trading 2.6% Higher - What's Next?July 2 at 2:26 AM | americanbankingnews.comTVRD Share News TodayJune 29 at 3:23 PM | uk.investing.comTvardi Therapeutics Sets Key Deadlines for 2026 MeetingJune 27, 2026 | theglobeandmail.comTvardi Therapeutics, Inc. Common StockJune 27, 2026 | fxempire.comFH.C. Wainwright Initiates a Buy Rating on Tvardi Therapeutics (TVRD)June 25, 2026 | theglobeandmail.comTvardi Therapeutics Shareholders Approve Directors and Governance MeasuresJune 11, 2026 | tipranks.comTvardi Therapeutics to Participate in Upcoming Investor EventsMay 21, 2026 | globenewswire.comOppenheimer Sticks to Its Buy Rating for Tvardi Therapeutics (TVRD)May 13, 2026 | theglobeandmail.comTvardi Therapeutics (TVRD) Receives a Buy from BTIGMay 11, 2026 | theglobeandmail.comTvardi: Q1 Earnings SnapshotMay 8, 2026 | wtop.comWTvardi Therapeutics Announces First Quarter 2026 Results and Provides Business UpdateMay 8, 2026 | globenewswire.comBarclays downgrades Tvardi Therapeutics (TVRD)April 21, 2026 | msn.comTvardi Therapeutics (TVRD) Price Target Decreased by 43.91% to 8.50April 9, 2026 | msn.comBarclays Reaffirms Their Hold Rating on Tvardi Therapeutics (TVRD)April 8, 2026 | theglobeandmail.comTvardi Therapeutics to Participate in the Raymond James Biotech Innovation SymposiumApril 2, 2026 | globenewswire.comTvardi: Q4 Earnings SnapshotApril 1, 2026 | stamfordadvocate.comSTvardi Therapeutics Announces Fourth Quarter and Full-Year 2025 Results and Provides Business UpdateMarch 31, 2026 | globenewswire.comTvardi Therapeutics to Participate in Upcoming Investor ConferencesFebruary 12, 2026 | markets.businessinsider.comWe're Keeping An Eye On Tvardi Therapeutics' (NASDAQ:TVRD) Cash Burn RateFebruary 7, 2026 | finance.yahoo.comTvardi Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare ConferenceJanuary 8, 2026 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesCheap Thrills: Why These 3 Entertainment Stocks Are SoaringBy Dan Schmidt | June 17, 2026Flying Under the Radar: Lockheed Martin's $2.8B Stealth SetupBy Jeffrey Neal Johnson | June 17, 2026Plot Twist: How the $110B Paramount-Warner Deal Rewrites MediaBy Jeffrey Neal Johnson | June 16, 2026The Netflix-Lionsgate Rumor Exposed a Bigger Shift in Media M&ABy Jeffrey Neal Johnson | June 19, 2026MGM Buyout: The House Doesn't Always WinBy Jeffrey Neal Johnson | June 2, 2026INM, NCEL, SNSE, and TVRD Company DescriptionsInMed Pharmaceuticals NASDAQ:INM$1.59 +0.04 (+2.58%) Closing price 07/1/2026 04:00 PM EasternExtended Trading$1.60 +0.01 (+0.63%) As of 07/1/2026 04:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.InMed Pharmaceuticals Inc., a clinical stage pharmaceutical company, develops a pipeline of prescription-based products. The company operates through two segments, the InMed and the BayMedica. The InMed segment researches and develops cannabinoid-based pharmaceuticals products. The BayMedica segment develops proprietary manufacturing technologies to produce and sell rare cannabinoids for the health and wellness industry. Its prescription-based products include rare cannabinoids and novel cannabinoid analogs for the treatment of diseases with high unmet medical needs. The company's lead product is INM-755, a cannabinol topical skin cream, completed Phase 2 clinical trial for the treatment of epidermolysis bullosa. It also develops INM-088, which is in preclinical studies for the treatment of glaucoma; and INM-900 for neurodegenerative diseases. In addition, the company offers IntegraSyn, an integrated biosynthesis-based manufacturing approach, for pharmaceutical-grade cannabinoids; and cannabichromene, cannabicitran, cannabidivarin, and tetrahydrocannabivarin. The company was formerly known as Cannabis Technologies Inc. and changed its name to InMed Pharmaceuticals Inc. in October 2014. InMed Pharmaceuticals Inc. was incorporated in 1981 and is headquartered in Vancouver, Canada.NLS Pharmaceutics NASDAQ:NCEL$3.85 +0.19 (+5.19%) As of 07/1/2026 04:00 PM EasternNLS Pharmaceutics AG, a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for patients with rare and complex central nervous system disorders. The company is focusing on the development of treatments for narcolepsy, idiopathic hypersomnia, and other rare sleep disorders, as well as neurodevelopmental disorders, such as attention deficit hyperactivity disorder (ADHD). Its lead product candidates include Quilience to treat excessive daytime sleepiness and cataplexy; and Nolazol for the treatment of ADHD. The company also developing NLS-4, a selective dopamine reuptake inhibitor to prevent rare sleep disorders; NLS-3, a repurposed reverse ester of methylphenidate for treatment of ADHD; NLS-8, a melatonin ML1A receptor agonist, improved scopolamine-induced amnesia; NLS-11, a norepinephrine and dopamine reuptake inhibitor and muscarinic M1, M2, M3 receptor antagonist; and NLS-12, a norepinephrine and dopamine reuptake inhibitor and muscarinic M4 receptor antagonist. NLS Pharmaceutics AG was incorporated in 2015 and is based in Zurich, Switzerland.Sensei Biotherapeutics NASDAQ:SNSE$14.14 +0.30 (+2.13%) Closing price 06/15/2026Extended Trading$14.14 0.00 (0.00%) As of 06/15/2026 07:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Sensei Biotherapeutics, Inc., an immuno-oncology company, engages in the discovery and development of therapeutics for cancer patients. The company's Tumor Microenvironment Activated Biologics platform is designed to generate highly selective therapeutics that disable immunosuppressive signals or activate immunostimulatory signals selectively in the tumor microenvironment. It also offers SNS-101, an active monoclonal antibody that is in clinical Phase 1/2 targeting the immune checkpoint VISTA for the treatment of solid tumors. The company's pipeline includes SNS-103 and SNS-102, an active monoclonal antibody, which are in early development stages for the treatment of solid tumors, as well as SNS-201 is a bispecific antibody targeting CD28. It has a collaboration with The University of Washington to conduct preclinical studies for its SNS-101 program. The company was formerly known as Panacea Pharmaceuticals, Inc. Sensei Biotherapeutics, Inc. was incorporated in 1999 and is headquartered in Rockville, Maryland.Tvardi Therapeutics NASDAQ:TVRD$1.95 +0.05 (+2.63%) Closing price 07/1/2026 04:00 PM EasternExtended Trading$1.86 -0.10 (-4.87%) As of 07:38 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Cara Therapeutics, Inc., an early commercial-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body's peripheral nervous system and immune cells. The company's lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis. Its product candidate includes Oral KORSUVA (difelikefalin), which has completed Phase II clinical trial to treat pruritus atopic dermatitis and pruritus non-dialysis-dependent chronic kidney disease (NDD-CKD) associated pruritus; and in Phase II clinical trial to treat pruritus chronic liver disease (CLD) primary biliary cholangitis (PBC) and notalgia paresthetica. The company has license agreements with Maruishi Pharmaceutical Co., Ltd to develop, manufacture, and commercialize drug products containing difelikefalin for acute pain and uremic pruritus in Japan; and Chong Kun Dang Pharmaceutical Corporation to develop, manufacture, and commercialize drug products containing difelikefalin in South Korea. Cara Therapeutics, Inc. was incorporated in 2004 and is based in Stamford, Connecticut. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Uber’s Waymo Detour Tests the Stock’s Robotaxi Bull Case Copper Stocks Are Getting a Bigger Spotlight as Gold’s Rally Cracks AirJoule Unveils Prime System, Clearing Path to Commercialization Comcast’s NBCUniversal Split Puts Broadband Back in Focus Nike Q4 Beat Masks Core Weakness as Analysts Cut Price Targets Ouster Is Breaking Out as a Physical AI Leader: Here's What's Driving the Move Meta’s WhatsApp Shakeup Could Put India at the Center of Its Next Growth Push Hershey Stock May Be Near a Sweet Spot as Cocoa Pressure Eases Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
